NY-AQARA
9.4.2024 09:01:58 CEST | Business Wire | Press release
Aqara, a leading provider of smart home solutions, today announced the availability of the Motion and Light Sensor P2, its new generation motion sensor built upon the Thread protocol and the industry-unifying Matter standard. The native Matter connectivity offers unparalleled compatibility across smart home platforms including Amazon Alexa, Apple Home, Google Home, and Samsung SmartThings1. With Matter's local networking capabilities, the P2 sensor ensures enhanced responsiveness and reliability.
“In the rapidly expanding global market for Passive Infrared (PIR) sensors, Aqara has achieved remarkable success, distributing over 100,000 units last year,” states Cathy You, Aqara Senior Vice President, Global Business and Strategy. “The launch of the Motion and Light Sensor P2, which combines our renowned sensor technology with the latest in connectivity protocols and standards, encapsulates our forward-thinking approach and our commitment to delivering smart home solutions that are ready for tomorrow's advancement.”
The Motion and Light Sensor P2 integrates an ultra-wide angle PIR motion sensor with a standalone illumination sensor, providing precise detection up to 7 meters (ca. 23 feet) and 170° horizontally2. This facilitates a range of use scenarios from automated lighting and security enhancement to climate control. The sensor also measures light intensity independently of motion detection3, enabling sophisticated lighting and window covering control for optimal comfort and energy efficiency. Engineered for longevity, the Motion and Light Sensor P2 boasts a robust battery life of up to two years, ensuring dependable operation with minimal maintenance.
As a Thread-enabled device, the Motion and Light Sensor P2 connects to any Matter controller with Thread Border Router functionality, and allows use across multiple compatible platforms thanks to Matter's multi-admin feature. Furthermore, the sensor offers a few Aqara Home exclusive features such as customizable sensitivity and detection timeout settings for tailored performance4. Users can fine-tune both parameters through the Aqara Home app, which requires Aqara's own Thread-enabled Matter controller, for example the upcoming Hub M3.
As part of Aqara’s expanding Thread-enabled product line, the Motion and Light Sensor P2 exemplifies the Company’s dedication to elevating smart home experiences through enhanced interoperability and simplicity. Additional Thread devices from Aqara are expected in the coming months, including the aforementioned Hub M3 and the retrofit home access solution Smart Lock U200.
The Motion and Light Sensor P2 is now available in Aqara’s Amazon brand stores in North America (US, Canada), Europe (France, Germany, Italy, Poland, Spain, UK) and Asia (Japan), as well as through select Aqara retailers worldwide5.
For more information on this sensor, please visit our website.
1. A Matter controller with Thread Border Router functionality is required for the connection to the corresponding Matter-enabled system.
2. Based on the internal lab test, measured under the ambient temperature of 25 °C (ca. 77 °F) and high sensitivity level.
3. Illumination sensing functionality is not available on Alexa at the time of launch.
4. By default, the sensor is set to medium sensitivity and a 30-second detection timeout.
5. Product availability may vary by retail channel.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409809799/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom